Down syndrome phenotype is complex and may present a combination of dysmorphic features, congenital heart disease and immunological deficiency. Ustekinumab for Treatment of Plaque Psoriasis in a Patient With Down Syndrome: Down syndrome (DS) is the most common chromosomal disorder and a major cause of mental retardation. Purchase Original Article. 08-01, English, Article, Report edition: Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.(SPECIAL TOPIC)(Report) Talamonti, Marina; Galluzzo, Marco; Chiricozzi, Andrea;. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. Down syndrome phenotype is complex and may present a combination of dysmorphic features, congenital heart disease and immunological deficiency. In the following article, we present our protocol for the Goeckerman therapy that is utilized specifically at the University of California, San Francisco.
Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sj gren syndrome. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. Medical and scientific articles about Psoriasis, written by M Galluzzo. 1 Article What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice. 4, Article, Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.
140 Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. This article provides a comprehensive review of the pharmacokinetics of ustekinumab, its safety profile, adverse effects, and use in pregnancy. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. Plaque psoriasis accounts for 90 of all people with psoriasis. Metabolic syndrome (abdominal obesity, hypertension, insulin resistance, dyslipidaemia). Biological therapies – etanercept, efalizumab, adalimumab, infliximab and ustekinumab – are recommended as a treatment option for adults with plaque psoriasis when the following criteria are met: 19 20 21 22.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The pharmacological characteristics and both the clinical efficacy and tolerability of ustekinumab are clearly proven in patients with chronic moderate to severe plaque psoriasis, including subjects with psoriatic onychopathy and psoriatic arthritis 8, 43 46. This aspect is particularly important to consider in case of metabolic syndrome comorbidity. It represents a masterpiece in the treatment of plaque psoriasis. The online version of this article (doi:10. In particular, patients with psoriasis respond to treatment interfering with lymphocyte activation, the tumor necrosis factor (TNF) pathway, agents blocking interleukin (IL)-17 or the IL-12/23p40 subunit. Commission for the treatment of moderate to severe chronic plaque psoriasis in adults who failed to respond to, who have a contraindication to or who are intolerant of systemic oral immunosuppressants. Ustekinumab treatment was associated with new-onset or worsening psoriatic arthritis in a series of seven patients with psoriasis. Symptoms of RA with Felty syndrome. All seven patients in the case series had well-controlled psoriasis on ustekinumab. Click Here to View Comments on this Article. We identified relevant articles by systematic electronic searches (Cochrane Library, Medline,). Chronic plaque psoriasis is a lifelong disease with a substantial impact on the physical well-being and quality of a patient s life. However, long-term treatment in patients with moderate to severe psoriasis is limited by the potential for toxic effects on organs, such as renal, hepatic or bone marrow, in addition to teratogenicity and malignancies that are associated with the traditional systemic therapies. Superficial spreading melanoma in a psoriatic plaque of a patient with psoriatic arthritis. J Dermatol. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment. J Dermatol. Multiple dermatofibromas in a patient with Down syndrome. J Dermatol. Pharmacokinetic factors and differences in the dynamics of cytokine down-regulation, coupled with varied responses of cell targets in joint, entheseal or skin lesions, may contribute to the delayed onset of ustekinumab peak response observed in PsA. All Versions of this Article:.
People that endure moderate to severe plaque psoriasis regularly report social and personal discomfort. In this case series, ustekinumab injections show an effective method of controlling chronic and recalcitrant plantar psoriasis. In general, palmo-plantar plaque psoriasis requires more potent topical medications to break down the scale and inflammation that the thickened and more traumatized skin in that area generates. Article Comments. Table of Contents previous Article next. Hepatitis Lupus-like syndrome Infliximab therapy Psoriasis. A 23-year-old female presented with generalized plaque psoriasis of 10 years duration. Her ANA titer went down to 1:160 (homogenous); 24 months later the condition remained stable with no relapse or recurrence of drug-related symptoms (table 1). Non-TNF blockers such as ustekinumab were helpful in this patient, in addition to other adjuvant medications to control here severe joint problems. 2013 August;169(2):458-63 as article that make the greatest impact on psoriasis research. Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. Down syndrome (DS) is the most common chromosomal disorder and a major cause of mental retardation. We have valuated the efficacy and safety of ustekinumab treatment in-patient with DS suffering from plaque type psoriasis.